{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T12:47:36Z","timestamp":1769345256834,"version":"3.49.0"},"reference-count":12,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2005,10,19]],"date-time":"2005-10-19T00:00:00Z","timestamp":1129680000000},"content-version":"vor","delay-in-days":3944,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[1995,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tolterodine, a novel compound intended for treatment of urgency and urge incontinence, has been characterized as a potent muscarinic receptor antagonist in pharmacological in vitro and in vivo studies. In cats, tolerodine was shown to reduce bladder pressure at doses significantly lower than those affecting salivation. To predict clinical effectiveness, an open pilot study was performed in healthy male volunteers. Efficacy was measured by cystometry and by spontaneously reported effects after administration of a single oral dose of tolterodine. 6.4 mg, given as a water solution. Tolterodine had distinct inhibitory effects on urinary bladder function, both at 1 and 5 hours post\u2010dose. At 1 hour, but not at 5 hours post\u2010dose tolterodine also significantly reduced stimulated salivation. In addition to the objectively demonstrated changes in urodynamic parameters, most volunteers experienced voiding difficulties. No significant changes in blood pressure, heart rate, or near point of accommodation were registered. Tolterodine, in the dosage used, was both objectively and subjectively shown to exert a marked inhibitory effect on micturition in healthy subjects, and the data suggest a more pronounced effect on bladder function than on salivation. \u00a9 1995 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/nau.1930140606","type":"journal-article","created":{"date-parts":[[2007,3,4]],"date-time":"2007-03-04T13:39:32Z","timestamp":1173015572000},"page":"647-655","source":"Crossref","is-referenced-by-count":90,"title":["Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity"],"prefix":"10.1002","volume":"14","author":[{"given":"M. M. S.","family":"Stahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sparf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mattiasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.\u2010E.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,10,19]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198835040-00006"},{"key":"e_1_2_1_3_1","first-page":"253","article-title":"The pharmacology of lower urinary tract smooth muscles and penile erectile tissues","volume":"45","author":"Andersson KE","year":"1993","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)45335-3"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.1955.sp001131"},{"key":"e_1_2_1_6_1","first-page":"435","article-title":"Tolterodine\u2014A new agent with tissue effect selectivity for urinary bladder","volume":"13","author":"Gillberg P\u2010G","year":"1994","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1985.tb06301.x"},{"key":"e_1_2_1_8_1","first-page":"433","article-title":"The in vitro pharmacological profile of tolterodine\u2014a new agent for the treatment of urinary urge incontinence","volume":"13","author":"Nilvebrant L","year":"1994","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_1_9_1","first-page":"523","article-title":"Interaction of tolterodine with cholinergic muscarinic receptors in human detrusor","volume":"14","author":"Nilvebrant L","year":"1995","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_1_10_1","first-page":"363","article-title":"Power differences between pairwise multiple comparisons","volume":"73","author":"Ramsey PH","year":"1978","journal-title":"J Am Slat Assoc"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1984.sp015386"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)53509-0"},{"key":"e_1_2_1_13_1","first-page":"43","volume-title":"Urodynamics. Principles, Practice and Application","author":"Wein AJ","year":"1994"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.1930140606","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.1930140606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T21:59:57Z","timestamp":1700517597000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.1930140606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1995,1]]}},"alternative-id":["10.1002\/nau.1930140606"],"URL":"https:\/\/doi.org\/10.1002\/nau.1930140606","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,1]]}}}